Summary: New research suggests dopamine’s role in movement is different than previously believed. Rather than directly controlling the force or speed of each action, dopamine appears to provide a necessary baseline that enables movement to occur. Experiments found that manipulating brief, subsecond dopamine spikes did not alter how vigorously animals moved, while restoring overall dopamine levels returned normal movement.
This shift in understanding could change strategies for treating movement disorders such as Parkinson’s disease. Instead of aiming to recreate fast signaling spikes, therapies that stabilize baseline dopamine may be a simpler and more effective target.
Key Facts:
- Rethinking Dopamine: Brief dopamine bursts did not change movement speed or strength in the study.
- Baseline Matters: Restoring baseline dopamine—not momentary spikes—improved motor performance.
- Treatment Insight: These findings suggest that maintaining steady dopamine levels may be a promising therapeutic approach for movement disorders.
Source: McGill University
A McGill-led study challenges the prevailing idea that dopamine’s rapid, subsecond spikes directly set the vigor of individual movements.
Published in Nature Neuroscience, the study shows that dopamine does not appear to specify the speed or force of each movement. Instead, dopamine functions more broadly as the chemical environment needed for the motor system to operate. The research team used precise, real-time measures of dopamine signaling combined with techniques to turn dopamine-producing cells on or off, and their results point toward a simpler view: baseline dopamine enables movement, while fast transients do not determine movement vigor.
“Our findings suggest we should rethink dopamine’s role in movement,” said senior author Nicolas Tritsch, Assistant Professor in McGill’s Department of Psychiatry and a researcher at the Douglas Research Centre. “Restoring dopamine to a normal level may be enough to improve movement. That could simplify how we think about treatment for Parkinson’s disease.”
Dopamine is widely recognized as essential for motor vigor—the capacity to move with strength and speed. In Parkinson’s disease, neurons that produce dopamine are progressively lost, leading to symptoms such as slowed movement, tremor, and balance impairment. Levodopa, the standard medication for Parkinson’s, reliably improves mobility, but the precise mechanism of its benefit has been debated. Recent recording technologies had revealed rapid dopamine spikes during movement, leading many to propose that these spikes directly control how vigorous an action will be.
The new study’s findings go against that idea. When researchers altered brief dopamine transients at the moment of movement, they observed no change in how forceful or fast the movement was. By contrast, levodopa improved movement by raising the brain’s tonic or baseline dopamine level, not by restoring rapid, subsecond fluctuations.
Measuring dopamine in real time
To investigate dopamine’s role, the team measured activity in the striatum of mice while animals performed a task that required pressing a weighted lever. They combined high-resolution dopamine sensors with optogenetic control of dopamine neurons—using light to increase or decrease cell activity at precise times. If subsecond spikes were the key drivers of vigor, then manipulating those spikes during a movement should change the action’s speed or force. It did not. Instead, increasing the overall availability of dopamine with levodopa restored normal movement, indicating the medication’s benefit depends on raising baseline dopamine.
A more precise target for treatment
More than 110,000 Canadians currently live with Parkinson’s disease, a number expected to rise as the population ages. A clearer explanation for why levodopa helps could guide the development of new treatments focused on maintaining steady dopamine levels rather than reproducing transient signals. Such an approach may open the path to therapies that are both more effective and have fewer off-target effects.
The findings also encourage revisiting older strategies. Dopamine receptor agonists—which stimulate dopamine receptors—have shown clinical benefit but sometimes caused side effects because they act broadly across brain circuits. By highlighting baseline dopamine as the critical factor, this research gives drug developers a more specific therapeutic goal: restore and maintain the overall dopamine tone required for movement without unnecessarily activating unrelated pathways.
Funding
The research received support from the Canada First Research Excellence Fund through the Healthy Brains, Healthy Lives initiative at McGill University and funding from the Fonds de Recherche du Québec.
Key Questions Answered:
A: No. The study indicates dopamine is necessary for movement but does not determine the precise speed or force of each action.
A: Levodopa raises baseline dopamine levels, restoring the overall chemical environment that the motor system needs to function.
A: Therapies may shift toward maintaining steady dopamine tone rather than trying to mimic fast spikes, potentially enabling safer and more targeted approaches.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context and clarification were provided by staff to improve readability and accuracy.
About this dopamine and neuroscience research news
Author: Keila DePape, McGill University
Source: McGill University
Contact: Keila DePape – McGill University
Image: The image is credited to Neuroscience News
Original Research: Open access. “Subsecond dopamine fluctuations do not specify the vigor of ongoing actions” by Nicolas Tritsch et al., published in Nature Neuroscience. The authors report that subsecond dopamine transients in the striatum of mice are neither required nor sufficient to specify the vigor of ongoing forelimb movements, with implications for understanding motor control in normal conditions and in Parkinson’s disease.
Abstract
Subsecond dopamine fluctuations do not specify the vigor of ongoing actions
Dopamine (DA) is essential for the production of vigorous actions, but how DA modifies the gain of motor commands remains unclear. This study shows that rapid, subsecond dopamine transients in the striatum of mice are neither required nor sufficient to specify the vigor of ongoing forelimb movements. These findings have important implications for understanding how dopamine contributes to motor control in healthy brains and in Parkinson’s disease, and they point toward baseline dopamine tone as a critical factor in enabling movement.